MedPath

Salbutamol

Generic Name
Salbutamol
Brand Names
Airomir, Airsupra, Combivent, Proair, Proventil, Ventolin
Drug Type
Small Molecule
Chemical Formula
C13H21NO3
CAS Number
18559-94-9
Unique Ingredient Identifier
QF8SVZ843E
Background

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Indication

Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.

Associated Conditions
Asthma, Asthmatic Bronchitis, Bronchial Asthma, Bronchoconstriction, Bronchospasm, Chronic Asthma, Chronic Bronchitis, Cough, Emphysema, Exacerbation of asthma, Exercise-Induced Bronchospasm, Hyperkalemia, Wheezing, Excess mucus or phlegm
Associated Therapies
Airway secretion clearance therapy, Bronchodilation

Study of Dose-response to Bronchodilator and Dose-finding in Child 2.5 to 6 Years - Study Golden

First Posted Date
2011-11-11
Last Posted Date
2023-02-06
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
90
Registration Number
NCT01470755
Locations
🇫🇷

Beydon, Paris, France

IPF Drug Deposition Study

Phase 1
Completed
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
First Posted Date
2011-10-21
Last Posted Date
2014-11-05
Lead Sponsor
Royal Brompton & Harefield NHS Foundation Trust
Target Recruit Count
10
Registration Number
NCT01457261
Locations
🇬🇧

Royal Brompton Hospital, London, United Kingdom

Use of Beta-agonists in Stable Severe Congestive Heart Failure

Not Applicable
Conditions
Ischemic Cardiomyopathy
Non-ischemic Cardiomyopathy
Heart Failure
Interventions
First Posted Date
2011-10-05
Last Posted Date
2011-10-05
Lead Sponsor
Rabin Medical Center
Target Recruit Count
30
Registration Number
NCT01447069
Locations
🇮🇱

Rabin medical center, Petah Tikva, Israel

The Effect of High Dose Salbutamol on Muscle Performance

Not Applicable
Conditions
Ergogenic Effects of Salbutamol in Healthy Males
Interventions
Drug: Placebo
Drug: salbutamol
First Posted Date
2011-08-12
Last Posted Date
2011-08-12
Lead Sponsor
Bispebjerg Hospital
Target Recruit Count
20
Registration Number
NCT01415596
Locations
🇩🇰

Bispebjerg Hospital, Copenhagen NW, Denmark

Nebulized Albuterol for Congestive Heart Failure Exacerbation

Phase 2
Withdrawn
Conditions
Congestive Heart Failure
Interventions
Drug: Normal Saline
Drug: Albuterol
First Posted Date
2011-06-17
Last Posted Date
2013-10-10
Lead Sponsor
University of California, San Francisco
Registration Number
NCT01375361
Locations
🇺🇸

University of California, San Francisco, California, United States

Salbutamol Tolerance Onset

Phase 4
Completed
Conditions
Asthma
Interventions
Drug: salbutamol
Drug: Placebo
First Posted Date
2011-04-19
Last Posted Date
2012-07-20
Lead Sponsor
University of Saskatchewan
Target Recruit Count
15
Registration Number
NCT01338311
Locations
🇨🇦

University of Saskatchewan, Saskatoon, Saskatchewan, Canada

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: Placebo (for Dupilumab)
Drug: Dupilumab
Drug: Fluticasone/Salmeterol combination therapy
Drug: Fluticasone monotherapy
Drug: Albuterol
Drug: Levalbuterol
First Posted Date
2011-03-11
Last Posted Date
2017-06-08
Lead Sponsor
Sanofi
Target Recruit Count
104
Registration Number
NCT01312961
Locations
🇺🇸

Investigational Site Number 840003, Minneapolis, Minnesota, United States

🇺🇸

Investigational Site Number 840006, Saint Louis, Missouri, United States

🇺🇸

Investigational Site Number 840047, Anaheim, California, United States

and more 47 locations

A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:

Phase 3
Completed
Conditions
COPD
Interventions
First Posted Date
2011-03-11
Last Posted Date
2017-02-01
Lead Sponsor
AstraZeneca
Target Recruit Count
626
Registration Number
NCT01313494

A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)

Completed
Conditions
Asthma
Chronic Bronchitis
Chronic Obstructive Pulmonary Disease (COPD)
Emphysema
Interventions
First Posted Date
2011-02-24
Last Posted Date
2012-06-22
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
306
Registration Number
NCT01302587
Locations
🇺🇸

Teva Clinical Study Site 10099, Seattle, Washington, United States

🇺🇸

Teva Clinical Study Site 10090, Indianapolis, Indiana, United States

🇺🇸

Teva Clinical Study Site 10097, Overland Park, Kansas, United States

and more 18 locations

A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol

Phase 1
Completed
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2010-12-20
Last Posted Date
2019-01-29
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
48
Registration Number
NCT01263197
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States

© Copyright 2025. All Rights Reserved by MedPath